Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus

Highlights ► Early vaccines miss a pentameric gH complex important for viral epithelial entry. ► We restored expression of the complex in AD169 virus for evaluation in animals. ► Virus with restored complex can induce. ► 10-fold higher neutralizing antibodies. ► Peak titers post vaccination within 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2012-12, Vol.30 (52), p.7469-7474
Hauptverfasser:	Fu, Tong-Ming, Wang, Dai, Freed, Daniel C, Tang, Aimin, Li, Fengsheng, He, Xi, Cole, Suzanne, Dubey, Sheri, Finnefrock, Adam C, ter Meulen, Jan, Shiver, John W, Casimiro, Danilo R
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Animals Antibodies, Neutralizing - blood Antibodies, Viral - blood Antigens Cloning conception Cytomegalovirus Cytomegalovirus - immunology Cytomegalovirus - physiology Cytomegalovirus Vaccines - administration & dosage Cytomegalovirus Vaccines - immunology epithelial cells Epithelial Cells - virology Female glycoproteins Human cytomegalovirus Human herpesvirus 5 immune response Immunogenicity Infections Macaca mulatta maternal immunity Mice Mice, Inbred BALB C monkeys Mutation neutralization neutralizing antibodies Neutralizing antibody Pentameric gH complex Proteins Rabbits seroprevalence Studies T-lymphocytes vaccination Vaccine Vaccines Viral epithelial tropism Viral infections Viral Proteins - genetics Viral Proteins - metabolism Viral Tropism virion virus replication Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► Early vaccines miss a pentameric gH complex important for viral epithelial entry. ► We restored expression of the complex in AD169 virus for evaluation in animals. ► Virus with restored complex can induce. ► 10-fold higher neutralizing antibodies. ► Peak titers post vaccination within 2–4-fold of those in HCMV positive subjects.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2012.10.053